Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
80 participants
INTERVENTIONAL
2019-08-01
2023-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A prospective randomized double blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24 h morphine consumption after posterior lumbar interbody fusion surgery.
Objectives:
The primary objective is to study the influence of a bilateral erector spinae block on 24h morphine consumption.
Endpoint:
The primary endpoint is the 24 h morphine consumption in mg. Secondary endpoints are intraoperative sufentanil requirement, total morphine during first 72 postoperative hours, NRS pain scores in rest and defined movement (moving to chair) at regular time intervals and Quality of Recovery 40 score (QoR-40) at fixed time intervals day 1 and 3 postoperatively
Population:
Patients undergoing posterior lumbar interbody fusion ranging 1 - 3 levels Phase 3
Number of sites Enrolling participants:
University Hospital Antwerp \&AZ KLINA Brasschaat
Description of study agent:
Bilateral erector spinae block: each block contains 20 ml levobupivacaine 0.25% + 5 mcg/ml epinephrine Study duration Until the required study population is met Participant duration 72 hours
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Erector Spine Block for Back Surgery
NCT03214536
Dexmedetomidine and Morphine as Adjuvants to US Guided Erector Spinae Plane Blocks in Elective Thoracic Surgeries
NCT05843344
Adding Dexmedetomidine to Bupivacaine for Bilateral Erector Spinae Block
NCT06231979
Erector Spinae Block With Ropivacaine and Dexmedetomidine on Opioid Consumption After Lumar Spine Surgeries
NCT05664542
Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block
NCT05590234
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Stratified randomization will be done according to gender, levels of surgery and site online with Q minim.The study medication will be prepared in identical premade syringes and numbered according to a computer generated block randomization list (1:1 ratio ESB:sham). Subjects will be assigned consecutive numbers upon inclusion to the study and receive the study medication from the corresponding numbered syringes. The study medication in syringes for injection will be prepared by an anesthesiologist neither involved in the study nor in the care of the patient, before handing it over to the investigators. The ESB-group will receive 20 ml Chirocaine 0,25%. The sham block group medication will receive 20 ml Nacl0,9%. The levobupivacaine and saline 0.9% are identical in appearance. All investigators, staff and patients will be blinded to the treatment groups. Epinephrine is added to the placebo block in order to prevent unblinding by increased heart rate or blood pressure. Unmasking will not occur until statistical analysis is complete.
Patients in the erector spinae block group will receive a bilateral ESB block with an injectate containing 20 ml of levobupivacaine 0.25% in each puncture. Patients allocated to the sham group receive a bilateral ESB block with each injectate containing 20 mL of NaCl 0.9% . The blocks will be performed by experts in the field of ultrasound guided locoregional anaesthesia namely dr D. van Aken, dr L. Sermeus and dr M.B. Breebaart who are also teachers for the BARA (Belgian Association of Regional Anaesthesia). The blocks will be performed preoperatively in a separate block room with ultrasound after placement of an iv line and application of standard monitoring (ECG, NIBP, saturation). The blocks will be placed as described by Chin et al. modified for lumbar level.8 First, the patient will be placed in the lateral or sitting position. A curve array probe or a high frequency linear probe, depending on the BMI of the patient, will be placed in a longitudinal position 2-3 cm lateral of the vertebral column. The transverse processes of the vertebrae at the (mid) level of surgery, the erector spinae muscle and the psoas muscle are identified. In case of two level surgery the transverse process of the upper level will be considered as the preferred target. Depending on the depth a 5 or 8 cm 22 G ultrasound needle (Pajunk) will be inserted with an in plane technique in a cephalad to caudad direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20 ml of the study medication will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
General anesthesia will then be induced in a standardized way with propofol 2-3mg/kg, sufentanil 15mcg and rocuronium 0.5mg/kg. After tracheal intubation anesthesia will be maintained with sevoflurane and intraoperative analgesia with sufentanil. The dosages of these agents will be determined at the discretion of the anesthesiologist. At the end of surgery patients will receive acetaminophen 1g IV, ketorolac (Taradyl, CSP Benelux) 0.5 mg/kg (max. 30 mg) IV and a morphine loading dose (0.1 mg/kg) IV to manage postoperative pain. Patients will be extubated in the operating theatre and admitted to the post anesthesia care unit (PACU). Postoperative pain in the PACU and on the ward will be treated with acetaminophen 1g IV round the clock (4 times daily) and by a patient controlled intravenous analgesia pump (PCIA) with morphine at a concentration of 1 mg/ml and dehydrobenzperidol (DHBP) 0.05 mg/ml. The PCIA will be set using a standardised protocol: no background administration of morphine, a bolus dose of 1.5 mL morphine with a lock-out interval of 8 minutes and an hourly limit of 7.5 mg. If pain management on the PACU is inadequate (NRS \> 3) additional boli of 1 mg morphine IV will be administered with the total additional dose of morphine limited to 0.15mg/kg morphine. In case NRS is still \> 3 an IV ketamine (Ketalar, Pfizer) bolus (0.2 mg/kg) will be given. All patients receive dexamethasone 5mg IV as postoperative nausea and vomiting (PONV) prophylaxis. If needed, this will be supplemented by ondansetron 4mg IV and if still insufficient with alizapride 50mg IV. Other study endpoints will be retrieved from the patient data management systems
The morphine consumption during the first 24 hours postoperatively will be extracted out of the PCIA pump. The total morphine dose requirement during the first 72 postoperative hours will also be extracted out of the PCIA pump. Pain scores at rest will be assessed with the numeric rating scale (NRS, 0=no pain 10= worst imaginable pain) and tested at regular time intervals: at the time of inclusion, at the PACU (T0 = arrival at Post Anesthesia Care Unit, T+15min, T+30min) and ward (twice daily- morning and evening until postoperative day 3) Pain scores during defined movement (first moving to chair and upright sitting) will be examined. Time to first mobilization in chair (in hours since T0) and time to first walk of twenty meters (in hours since T0) will be noted in the patients study diary. The quality of recovery 40 score (QoR-40) will be calculated out of a series of questions patients are required to answer at day 1 and 3 postoperatively. The QoR-40 is a widely used and extensively validated measure of quality of recovery. It is a 40-item questionnaire on quality of recovery from anesthesia, that has been shown to measure health status after surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESB group
Erector Spinae plane block with 20 ml levobupivacaine 0,25% on each side. General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.
Postoperative analgesia with Ketorolac (0,5 mg/kg), paracetamol 1000 mg (4 times/ day) and Morphine PCA. Dexamethasone is administered for the prevention of nausea.
Erector spinae plane block
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Levobupivacaine 0,25%
20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
spine fusion
fusion of lumbar vertebral body on 1 or two levels
Sufentanil
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
propofol
induction agent for general anaesthesia ( 2-3 mg/kg)
Rocuronium Bromide
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
sevoflurane
inhalation aesthetic used for the maintenance of general anaesthesia
paracetamol
postoperative drug for analgesia ( 1 gram 4/day)
Ketorolac
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
morphine pca
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Dexamethasone
drug given during general anaesthesia to prevent postoperative nausea
Morphine
loading dose morhine 0,1 mg/kg at the end of surgery
SHAM group
Erector Spinae plane block with 20 ml NaCl 0,9% on each side General anesthesia with 15 mcg sufentanil, 2-3 mg/kg propofol and 0,5 mg/kg Rocuronium Bromide during spine fusion surgery (1 or two intervertebral levels). Maintainance of general anesthesia with sevoflurane.Postoperative analgesia with Ketorolac (0,5 mg/kg, paracetamol 1000 mg 4times/ day and Morphne PCA .Dexamethasone is administered for the prevention of nausea.
Erector spinae plane block
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
spine fusion
fusion of lumbar vertebral body on 1 or two levels
NaCL 0,9%
20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Sufentanil
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
propofol
induction agent for general anaesthesia ( 2-3 mg/kg)
Rocuronium Bromide
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
sevoflurane
inhalation aesthetic used for the maintenance of general anaesthesia
paracetamol
postoperative drug for analgesia ( 1 gram 4/day)
Ketorolac
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
morphine pca
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Dexamethasone
drug given during general anaesthesia to prevent postoperative nausea
Morphine
loading dose morhine 0,1 mg/kg at the end of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Erector spinae plane block
Ultrasound guided deposition infiltration between a lumbar transverse proces and the erector spine muscle
Levobupivacaine 0,25%
20 ml levobupivacaine 0,25% used for the infiltration between the transverse process and the erector spinal muscle
spine fusion
fusion of lumbar vertebral body on 1 or two levels
NaCL 0,9%
20 ml solution used for the infiltration between the transverse process and th erector spinal muscle
Sufentanil
opioid used for the preoperative analgesia for back surgery during general anaesthesia ( 15 mag)
propofol
induction agent for general anaesthesia ( 2-3 mg/kg)
Rocuronium Bromide
muscle relaxant used during general anaesthesia ( 0,5 mg/kg)
sevoflurane
inhalation aesthetic used for the maintenance of general anaesthesia
paracetamol
postoperative drug for analgesia ( 1 gram 4/day)
Ketorolac
non steroidal into inflammation drug used for postoperative analgesia (0,5 mg/kg)
morphine pca
postoperative morphine pomp, controlled by the patient. ( bolus 1 mg, lockout 8 minutes) the solution contains morphine 1 mg/ml + dehydrobenzperidol 0,05 mg/ml
Dexamethasone
drug given during general anaesthesia to prevent postoperative nausea
Morphine
loading dose morhine 0,1 mg/kg at the end of surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologist (ASA) score of 1 - 3
* Age 18 - 75 year
* Normal liver and renal function
Exclusion Criteria
* BMI \< 16 or BMI \> 35
* Allergy to one or more substances of the study medication (= levobupivacaine, dexamethasone, propofol, sufentanil, rocuronium, ketorolac, morphine, ketamine, DHBP, ondansetron, alizapride)
* Chronic strong opioid use (\>3 intakes per week)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr M. B. Breebaart
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr M. B. Breebaart
senior member of staff anesthesiology department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AZ KLina
Brasschaat, Antwerp, Belgium
University Hospital Antwerp
Antwerp, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Olivier Defre, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Breebaart MB, Van Aken D, De Fre O, Sermeus L, Kamerling N, de Jong L, Michielsen J, Roelant E, Saldien V, Versyck B. A prospective randomized double-blind trial of the efficacy of a bilateral lumbar erector spinae block on the 24h morphine consumption after posterior lumbar inter-body fusion surgery. Trials. 2019 Jul 17;20(1):441. doi: 10.1186/s13063-019-3541-y.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B300201837508
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.